VLA

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Retrieved on: 
星期一, 六月 20, 2022
Heart, Fever, FDA, Fatigue, Senior, COVID-19, Arthralgia, Safety, Science, Erythema migrans, Vaccine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Arthritis, News, Company, Myalgia, Carditis, Euronext Paris, Human, Fast Track, LinkedIn, Infection, Saint-Herblain, Global Health, Disease, Joint, Vaccination, BLA, YouTube, VLA, Program, Bacteria, PFE, Nasdaq, Partnership, Borrelia burgdorferi, Twitter, Food, Facebook, Biologics license application, Chikungunya, Headache, NYSE, Valneva SE, Nervous system, Pharmaceutical industry, Security (finance), Ixodes, Lyme disease, Pfizer

Valneva is planning to use the proceeds from Pfizers equity investment to support its Phase 3 development contribution to the Lyme disease program.

Key Points: 
  • Valneva is planning to use the proceeds from Pfizers equity investment to support its Phase 3 development contribution to the Lyme disease program.
  • In addition, Valneva and Pfizer updated the terms of their collaboration and license agreement which they announced on April 30, 20201.
  • Valneva will now fund 40% of the remaining shared development costs compared to 30% in the initial agreement.
  • Pfizer will pay Valneva tiered royalties ranging from 14% to 22%, compared to royalties starting at 19% in the initial agreement.

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Retrieved on: 
星期一, 六月 20, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Science, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Euronext Paris, LinkedIn, Infection, Disease, BLA, Clinical trial, PFE, U.S. Securities and Exchange Commission, Chikungunya, Nervous system, Time, Heart, Fever, Patent, Arthralgia, News, Fast Track, Vaccination, YouTube, VLA, Intention, Bacteria, Nasdaq, Twitter, FDA, Fatigue, COVID-19, Achievement, Myalgia, Carditis, Global Health, Joint, Biologics license application, Multimedia, NYSE, Risk, Senior, Safety, Erythema migrans, Vaccine, Arthritis, Company, Human, Research, Program, Partnership, Borrelia burgdorferi, Food, Facebook, Headache, Pharmaceutical industry, Security (finance), Valneva SE, Ixodes, Lyme disease, Pfizer

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.

Key Points: 
  • Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15.
  • Valneva is planning to use the proceeds from Pfizers equity investment to support its Phase 3 development contribution to the Lyme disease program.
  • In addition, Valneva and Pfizer updated the terms of their collaboration and license agreement which they announced on April 30, 20201.
  • Pfizer will pay Valneva tiered royalties ranging from 14% to 22%, compared to royalties starting at 19% in the initial agreement.

Valneva Announces Settlement Agreement with the UK Government

Retrieved on: 
星期三, 六月 15, 2022
CpG, COVID-19, Vaccine, Technology, Vero, Government, 1018, Company, Euronext Paris, Lyme disease, HMG, Infection, Saint-Herblain, Vaccination, VLA, VLA2001, Severe acute respiratory syndrome coronavirus 2, Corporate governance in the United Kingdom, Nasdaq, EMA, United Kingdom, Chikungunya, Pharmaceutical industry, Lease

Saint-Herblain (France), June 15, 2022 Valneva SE , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the United Kingdom (HMG) in relation to the termination of the supply agreement for Valnevas COVID-19 vaccine candidate, VLA2001.

Key Points: 
  • Saint-Herblain (France), June 15, 2022 Valneva SE , (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the United Kingdom (HMG) in relation to the termination of the supply agreement for Valnevas COVID-19 vaccine candidate, VLA2001.
  • The settlement agreement resolves certain matters relating to the obligations of the Company and HMG following the termination of the supply agreement and in relation to the separate agreement relating to clinical trials of VLA2001 in the United Kingdom, which remains in place.
  • The Company continues to have certain other obligations pursuant to provisions of the supply agreement that survive its termination.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001

Retrieved on: 
星期五, 六月 10, 2022
Vaccination, Marketing, Saint-Herblain, Lyme disease, Company, Program, Euronext Paris, EMA, European Medicines Agency, VLA, EC, Committee, European Directive on Traditional Herbal Medicinal Products, Nasdaq, 1018, CHMP, Vaccine, Technology, APA, Infection, Committee for Medicinal Products for Human Use, COVID-19, VLA2001, Union, Severe acute respiratory syndrome coronavirus 2, Royal commission, Public health, European Commission, Vero, CpG, Chikungunya

Saint-Herblain (France), June 10, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provides an update on its European inactivated whole-virus COVID-19 vaccine candidate VLA2001.

Key Points: 
  • Saint-Herblain (France), June 10, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provides an update on its European inactivated whole-virus COVID-19 vaccine candidate VLA2001.
  • However, the preliminary, unofficial volume indications received from the EC would not be sufficient to ensure the sustainability of Valnevas COVID-19 vaccine program.
  • Additionally, market research studies in six European countries indicated material interest in an inactivated COVID-19 vaccine for primary or booster vaccination.
  • Valneva also continues to work with agencies outside of the European Union for potential future approvals and additional purchase agreements.

Valneva Joins Euronext’s Tech Leaders Index

Retrieved on: 
星期三, 六月 8, 2022
VLA, Vaccine, Lyme disease, Company, Infection, COVID-19, Euronext Paris, Nasdaq, Chikungunya, Euronext

Saint Herblain (France), June 8, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.

Key Points: 
  • Saint Herblain (France), June 8, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.
  • The Euronext Tech Leaders Index is composed of 100+ European Tech companies, which were identified by Euronext either to be leaders in their field or to have a particularly strong growth profile.
  • It aims to strengthen the European Tech sector and be a catalyst for the next generation of Tech leaders.
  • The Euronext Tech Leaders initiative is supported by a powerful network of partners including global investment banks as well as French state-owned investment arm Groupe Caisse des Dpts.

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8

Retrieved on: 
星期二, 六月 7, 2022
LMIC, Human, Lyme disease, Saint-Herblain, Infection, Headache, Company, Genome, Conference, Marketing, Euronext Paris, Nausea, CEST, VLA, European, Travel medicine, CHIKV, Fever, Nasdaq, Aedes, Vaccine, Mortality, Disease, Assistant, Risk, COVID-19, MD, Population, CEPI, Alphavirus, Rash, Medical device, Pharmaceutical industry, Chikungunya, Valneva SE

Vera Brger, Director Clinical Strategy at Valneva, will present an abstract on the clinical development of VLA1553.

Key Points: 
  • Vera Brger, Director Clinical Strategy at Valneva, will present an abstract on the clinical development of VLA1553.
  • In addition, Valneva will host a symposium on Friday, June 10, 2022 at 12:30 p.m. CEST.
  • Valneva, a gold sponsor of NECTM8, will have a display in the exhibit area at booth #8.
  • VLA1553 is a live-attenuated, single dose investigational vaccine candidate targeting the chikungunya virus, which has spread to over 120 countries.

Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference

Retrieved on: 
星期五, 六月 3, 2022
United Kingdom, Marketing, Lyme disease, Saint-Herblain, Adult, Company, Conference, Euronext Paris, US Foods, Food, VLA, Jefferies, Conditional, Webcast, Pfizer, Nasdaq, Vaccine, Infection, COVID-19, Chikungunya, Valneva SE

Additionally, in April 2022, Valneva and its partner Pfizer reported first positive pediatric results for their Lyme disease vaccine candidate VLA155.

Key Points: 
  • Additionally, in April 2022, Valneva and its partner Pfizer reported first positive pediatric results for their Lyme disease vaccine candidate VLA155.
  • The fireside chat at the Jefferies conference will take place on June 9, 2022 at 11:30am EDT (17:30 CEST) and will be accessible live via the following link, https://wsw.com/webcast/jeff240/valn/1848225 .
  • A replay of the webcast will be available following the live events in the Investor section of the Valneva website at www.valneva.com .
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Valneva Announces the Availability of Documentation for its Shareholder Meetings

Retrieved on: 
星期四, 六月 2, 2022
Combined, Company, Euronext Paris, InterContinental Paris Le Grand Hotel, CEST, VLA, Special, Nasdaq, Hotel, Convertible, Documentation, Security (finance), Meeting

Saint Herblain (France), June 2, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting and Special Meeting of holders of Convertible Preferred Shares.

Key Points: 
  • Saint Herblain (France), June 2, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting and Special Meeting of holders of Convertible Preferred Shares.
  • Documents and information relating to the Meetings are available on Valnevas website ( www.valneva.com ) in the Investors/General Meetings section.
  • Shareholders can also obtain the Combined General Meeting and Special Meeting documents upon request to the Company by sending an email to the following address: [email protected] .
  • The Company also recommends that shareholders regularly consult the sections related to the the Combined General Meeting and Special Meeting on its website, www.valneva.com .

Valneva Appoints Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board

Retrieved on: 
星期二, 五月 31, 2022
Department, EMDS, Company, Doctor of Philosophy, Biochemistry, Max Perutz Labs, Saint-Herblain, Journal, Nasdaq, Infection, Vaccine, Education, COVID-19, VLA, Genetics, Research, WHO, Decker, Immunity, EMA, University, Euronext Paris, United States Air Force Scientific Advisory Board, Lyme disease, PEI, Biomedicine, Chikungunya, SAB, M.D, Pharmaceutical industry, Microbiology, MD

Saint-Herblain (France), May 31, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the appointment of leading vaccine experts Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board (SAB).

Key Points: 
  • Saint-Herblain (France), May 31, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the appointment of leading vaccine experts Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board (SAB).
  • Dr. Thomas Decker is a professor of Immunobiology at the Max Perutz Labs of the University of Vienna.
  • During his career, Dr. Decker also served as a consultant for several pharmaceutical companies.
  • Dr. Pfleiderer significantly contributed to numerous EMA and WHO guidelines on scientific and regulatory issues related to vaccines.

Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
星期三, 五月 25, 2022
Rash, Fever, Genome, Company, Nausea, Population, CEPI, Ageing, Food, Disease, US Foods, Aedes, Nasdaq, Alphavirus, European Medicines Agency, Infection, DSMB, Vaccine, European, COVID-19, Mortality, VLA, Marketing, BLA, Vaccination, GMT (TV programme), FDA, CHIKV, Priority review, GMT, Immunization, Data monitoring committee, Human, EMA, Safety, Travel, Euronext Paris, Confidence interval, Breakthrough therapy, Headache, Lyme disease, PRV, LMIC, Pharmaceutical industry, Pfizer, Chikungunya

Saint Herblain (France), May 25, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.

Key Points: 
  • Saint Herblain (France), May 25, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553.
  • Chikungunya is a major, growing and unmet public health threat, yet no vaccine or specific treatment is currently available to prevent this debilitating disease.
  • Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.